Hikma Pharmaceuticals PLC engages in the development, manufacture, and marketing of generic and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms. The company operates primarily in the United States,…
Analysis
Bargain bin
Hikma Pharmaceuticals PLC falls in the bargain bin: the price is low relative to peers, but the business metrics give reason to pause.
The price is attractive. You pay 10.2× its owner earnings: the cash an owner could take out each year, which is in the historically attractive zone. At today's price, the market is assuming roughly -3% yearly growth; analysts expect 7%. The price, in other words, assumes less than the experts do.
The trajectory is tepid and the balance sheet is adequate. The company scores 14/20 on our value-creation score: strong value creator.
Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.
360° rank · history
1007550250
Jan 202368
92
2023202420252026
All-time high
96
Mar 2026
All-time low
68
Jan 2023
Average rank
86
across all years
Detailed & Historical Ranks
Deep dive into 15 detailed ranks and 3 years of history.
Current202520242023
Price/Sales
89
52
67
75
Price/Earnings
68
63
75
83
Price/Book
73
42
52
64
Dividend Yield
89
88
76
72
Value (overall)
95
88
87
83
Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.